⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.
Explore Prof. Wong's insights on MASLD treatment advancements from AASLD, featuring key drugs like Resmetirom, Lanifibranor, and Semaglutide with a focus on Lanifibranor
On International NASH Day 2023, PanNASH amplifies the importance of NASH awareness, education, and action. Learn about the complex multisystem nature of NASH, the potential of PPAR agonists in NASH management, and the role of healthcare professionals in delivering effective, patient-centered care. Discover how PanNASH resources are empowering the medical community and join us in taking action against NASH.
PanNASH speaker; Dr. Stephen Harrison takes part in the Nordic NASH symposium which aims to discuss management and diagnosis strategies of improving outcomes for patients with non-alcoholic steatohepatitis (NASH)
The circadian clock controls rhythms responsible for regulating bodily functions, e.g., appropriate eating times. When this clock becomes disrupted due to factors such as irregular daily eating patterns or weekly schedules, it instead promotes lipid dysregulation, oxidative stress, and inflammation.
Nonalcoholic fatty liver disease (NAFLD) is characterised by the presence of hepatic steatosis without significant alcohol consumption or concomitant liver disease. Patients with NAFLD-related cirrhosis are at a high risk of developing liver complications, including hepatocellular carcinoma (HCC).
MAFLD and inflammatory bowel disease: a prospective cohort study
Coffee achieves its beneficial effects through modulation of insulin resistance in a NAFLD mouse model
In this study, F. Barrow et al. (University of Minnesota Medical School, Minneapolis, USA) report that NASH livers accumulate B cells with elevated pro-inflammatory cytokine secretion .....
In this review, A. Santos-Laso et al. (Marqués de Valdecilla University Hospital, Valdecilla Biomedical Research Institute, Santander, Spain) summarise the key aspects of NAFLD .....
Although the term 'fatty liver hepatitis' first appeared in 1962, it was in 1980 that the term 'non-alcoholic steatohepatitis' (NASH) was coined and the histopathological.....
In this article, P. M. Abuja et al. (Medical University of Graz, Austria) propose that steatohepatitis develops in four phases with transitions, priming triggering, adaptation....